|
3
|
Dreicer R, Roth B, Petrylak D, Agus D, Meyers M, Esseltine D, Rodriquez D, Oppedisano P, Wang K, Boral A. Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4654] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. Dreicer
- Cleveland Clinic Foundation, Cleveland, OH; Vanderbilt-Ingram Cancer Center, Nashville, TN; Columbia University, New York, NY; Cedars-Sinai Prostate Cancer Ctr, Los Angeles, CA; Aventis Oncology, Bridgewater, NJ; Millenium Pharmaceuticals, Cambridge, MA
| | - B. Roth
- Cleveland Clinic Foundation, Cleveland, OH; Vanderbilt-Ingram Cancer Center, Nashville, TN; Columbia University, New York, NY; Cedars-Sinai Prostate Cancer Ctr, Los Angeles, CA; Aventis Oncology, Bridgewater, NJ; Millenium Pharmaceuticals, Cambridge, MA
| | - D. Petrylak
- Cleveland Clinic Foundation, Cleveland, OH; Vanderbilt-Ingram Cancer Center, Nashville, TN; Columbia University, New York, NY; Cedars-Sinai Prostate Cancer Ctr, Los Angeles, CA; Aventis Oncology, Bridgewater, NJ; Millenium Pharmaceuticals, Cambridge, MA
| | - D. Agus
- Cleveland Clinic Foundation, Cleveland, OH; Vanderbilt-Ingram Cancer Center, Nashville, TN; Columbia University, New York, NY; Cedars-Sinai Prostate Cancer Ctr, Los Angeles, CA; Aventis Oncology, Bridgewater, NJ; Millenium Pharmaceuticals, Cambridge, MA
| | - M. Meyers
- Cleveland Clinic Foundation, Cleveland, OH; Vanderbilt-Ingram Cancer Center, Nashville, TN; Columbia University, New York, NY; Cedars-Sinai Prostate Cancer Ctr, Los Angeles, CA; Aventis Oncology, Bridgewater, NJ; Millenium Pharmaceuticals, Cambridge, MA
| | - D. Esseltine
- Cleveland Clinic Foundation, Cleveland, OH; Vanderbilt-Ingram Cancer Center, Nashville, TN; Columbia University, New York, NY; Cedars-Sinai Prostate Cancer Ctr, Los Angeles, CA; Aventis Oncology, Bridgewater, NJ; Millenium Pharmaceuticals, Cambridge, MA
| | - D. Rodriquez
- Cleveland Clinic Foundation, Cleveland, OH; Vanderbilt-Ingram Cancer Center, Nashville, TN; Columbia University, New York, NY; Cedars-Sinai Prostate Cancer Ctr, Los Angeles, CA; Aventis Oncology, Bridgewater, NJ; Millenium Pharmaceuticals, Cambridge, MA
| | - P. Oppedisano
- Cleveland Clinic Foundation, Cleveland, OH; Vanderbilt-Ingram Cancer Center, Nashville, TN; Columbia University, New York, NY; Cedars-Sinai Prostate Cancer Ctr, Los Angeles, CA; Aventis Oncology, Bridgewater, NJ; Millenium Pharmaceuticals, Cambridge, MA
| | - K. Wang
- Cleveland Clinic Foundation, Cleveland, OH; Vanderbilt-Ingram Cancer Center, Nashville, TN; Columbia University, New York, NY; Cedars-Sinai Prostate Cancer Ctr, Los Angeles, CA; Aventis Oncology, Bridgewater, NJ; Millenium Pharmaceuticals, Cambridge, MA
| | - A. Boral
- Cleveland Clinic Foundation, Cleveland, OH; Vanderbilt-Ingram Cancer Center, Nashville, TN; Columbia University, New York, NY; Cedars-Sinai Prostate Cancer Ctr, Los Angeles, CA; Aventis Oncology, Bridgewater, NJ; Millenium Pharmaceuticals, Cambridge, MA
| |
Collapse
|